All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

SOHO 2019 | What is the role of CAR T-cell therapy in chronic lymphocytic leukemia (CLL)?

Featured:

Tanya SiddiqiTanya Siddiqi

Sep 20, 2019


During SOHO 2019, Houston, US, Dr. Tanya Siddiqi from City of Hope Comprehensive Cancer Center, Duarte, US, spoke to the Lymphoma Hub about the potential of CAR T-cell therapy in chronic lymphocytic leukemia (CLL). She describes how those therapies, alone or in combination with ibrutinib, show efficacy in patients who relapse on small molecule inhibitors. She also highlights the recent report on the first set of patients, who received CAR T-cell therapy and continue to be in a complete remission nine years later.

What is the role of CAR T-cell therapy in chronic lymphocytic leukemia (CLL)?

Your opinion matters

What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?